Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Viability scores of 3 = motile, no changes to morphology and transparency, 2 = reduced motility and/or some damage to tegument as well as reduced transparency and increased granularity, 1 = severe reduction of motility and/or damage to tegument with high opacity and high granularity, and 0 = dead
Potential Benefits in Research
We are single-minded about providing trusted investment products and advisory services
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia
US$ 26.97
US$ 26.78
US$ 20.40
US$ 20.13
US$ 27.97
US$ 28.74
US$ 29.88
US$ 22.70
US$ 23.49
US$ 29.77
US$ 20.90
US$ 24.32
US$ 28.77
US$ 29.20
US$ 26.39
US$ 28.81
